Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Aug 13,2020
Application of Solid Dispersion Technology in Formulation Development
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor.
More
Application of Solid Dispersion Technology in Formulation Development
Jun 30,2020
Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research
Chuansha, Shanghai, June 29, 2020. — Convalife and Medicilon signed a strategic pact, initiating a long-term cooperation between the two companies. Based on previous cooperation
More
Convalife and Medicilon announced a strategic pact to jointly conduct preclinical research
Jun 15,2020
Medicilon will participate 2020 SAPA Healthcare Investment Forum & Roadshow
Due to the COVID-19 pandemic, the 2020 SAPA Healthcare Investment Forum & Roadshow will be divided in 2 parts.  Part I will be hosted as
More
Medicilon will participate 2020 SAPA Healthcare Investment Forum & Roadshow
Jun 04,2020
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Congratualtions to Medicilon's partner, Bio-Thera, on obtaining NMPA's approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of
More
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Jun 01,2020
Medicilon received the "Most Improved in the Science and Technology” award
Led by Dr. CHUN-LIN CHEN, the founder and CEO of Shanghai Medicilon Inc., the entreprenuer team in Medicilon received the "Most Improved in the Science and Technology” award presented by Pudong New Area.
More
Medicilon received the "Most Improved in the Science and Technology” award
Apr 22,2020
Medicilon Preclinical Research-Mouse Tumor Model
As the incidence and mortality of cancer have increased year by year, cancer has become the primary enemy threatening human health. Therefore, more and more
More
Medicilon Preclinical Research-Mouse Tumor Model
Apr 21,2020
Formulation Research of Innovative Drugs
Zhangjiang Runhe International Office Garden Opened On April 15, 2020, the opening ceremony of Zhangjiang Runhe International Office Garden was successfully held.  The Member of
More
Formulation Research of Innovative Drugs
Apr 17,2020
Medicilon entered Zhangjiang Runhe International Office Garden as the first batch of contracted enterprises
Malignant tumors, Alzheimer's disease, diabetes, rheumatoid arthritis… These intractable diseases that threaten human health have long plagued us, bringing pain and suffering to unfortunate patients,
More
Medicilon entered Zhangjiang Runhe International Office Garden as the first batch of contracted enterprises
Apr 01,2020
Medicilon CMC-Formulation Department
In 2019, Medicilon has had an extraordinary year. The steadily developing Medicilon made a huge accumulation in 2019 and achieved a qualitative leap.  Let us
More
Medicilon CMC-Formulation Department
Mar 11,2020
Medicilon Drug Discovery - Chemistry Department
The Medicilon Chemistry Department is a professional, efficient, and well-qualified R&D team. The team has more than 40% of employees with a master's degree, doctor's degree, or above.
More
Medicilon Drug Discovery - Chemistry Department
Mar 10,2020
API Process Development of the New Drug IND Stage
In the development of innovative drugs, the progress of the process development of the IND phase of the API often directly affects the subsequent formulation
More
API Process Development of the New Drug IND Stage
Feb 02,2020
Taking the Responsibility and Praying for the Peace; Medicilon helps to fight the coronavirus by providing funds and technology
During the Spring Festival, China has been facing a difficult time as the coronavirus spread all over the country.  In order to stop the coronavirus,
More
Taking the Responsibility and Praying for the Peace; Medicilon helps to fight the coronavirus by providing funds and technology
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->